PRESS RELEASES |
2019
December 2019
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
October 2019
Osivax Extends Executive Team to strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate
September 2019
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
July 2019
Osivax Secures EUR 8 Million of Financing through a Series A Round
January 2019
Osivax appoints Dr. Paul Willems as Chief Medical Officer
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
October 2019
Osivax Extends Executive Team to strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate
September 2019
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
July 2019
Osivax Secures EUR 8 Million of Financing through a Series A Round
January 2019
Osivax appoints Dr. Paul Willems as Chief Medical Officer
2018
June 2018
Approval of Osivax’ First in Human Clinical Trial for its Universal Influenza Vaccine Candidate
April 2018
Osivax strengthens its collaboration with the German Cancer Research Center (DKFZ)
February 2018
Osivax appoints Prof. Jeffrey Almond, pre-eminent Vaccinologist, as Chairman of its Scientific Advisory Board
January 2018
Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer
Approval of Osivax’ First in Human Clinical Trial for its Universal Influenza Vaccine Candidate
April 2018
Osivax strengthens its collaboration with the German Cancer Research Center (DKFZ)
February 2018
Osivax appoints Prof. Jeffrey Almond, pre-eminent Vaccinologist, as Chairman of its Scientific Advisory Board
January 2018
Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer